HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sign Of Normalcy? US FDA Schedules Meeting But Pauses Non-COVID Guidance Development

Executive Summary

As the agency and country plot the steps to reopening, a full resumption of activities still seems a long way off.

You may also be interested in...



US FDA May Publish Pre-Recorded Presentations Before Virtual Advisory Committee Meetings

The move is intended to streamline virtual advisory committee meetings, FDA official says.

OTC Decisions In May: Esomeprazole For Sun Pharma, Guaifenesin For Granules India, More NRTs For PLD During Slow Month For Approvals

CDER representative says staff’s time available for drug applications currently is affected by the FDA having employees work remotely in response to the novel coronavirus pandemic.

No End In Sight: FDA Postpones Another In-Person Meeting Due To COVID-19

The US agency had planned to hold an in-person meeting of its ophthalmic advisory committee in early June, indicating hope that things would be back to some form of normal by then. But due to the ongoing coronavirus pandemic, it has postponed that meeting until further notice.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel